What are you looking for?
The educational materials for patients or educational materials for healthcare professionals included here are additional risk minimisation measures that are intended to promote the safe and effective use of the medicinal product. Risk minimisation measures are a regulatory requirement and are part of the RMP (Risk Management Plans) approved by the EMA. They are assessed at national level by the HPRA for approval in Ireland.
Beovu
Exelon
Exjade
Gilenya
Kymriah
Lucentis
Mayzent
Myfortic
May 2025 | FA-11428224
Reporting of side effects:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.
Image
